Myriad Genetics | MYGN - Operating Profit


Myriad Genetics reported $-3M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Agilent USD 353M 90M Dec/2025
Becton, Dickinson and Co. USD 663M 163M Dec/2025
Bio-Rad Laboratories USD 63.9M 13.2M Sep/2025
Bruker USD 76.3M 7.6M Dec/2025
Danaher USD 1.5B 348M Dec/2025
Hologic USD 237M 16M Dec/2025
Illumina USD 256M 6M Dec/2025
J&J USD 5.59B 1.81B Dec/2025
Mettler Toledo International USD 351.93M 57.73M Dec/2025
Myriad Genetics USD -3M 20.3M Dec/2025
OraSure Technologies USD -13.59M 2.13M Dec/2025
Pacific Biosciences Of California USD -53.19M 35.08M Dec/2025
Quest Diagnostics USD 386M 0 Dec/2025
Quidel USD -37.3M 667.5M Dec/2025
Repligen USD 19.97M 7.29M Dec/2025
Revvity USD 145.83M 47.49M Dec/2025
Standard Biotools USD -21.92M 1.55M Dec/2025
Thermo Fisher Scientific USD 2.3B 226M Dec/2025
Veracyte USD 24.63M 1.52M Dec/2025
Waters USD 270.52M 78.4M Dec/2025